Abstract
Previously, we demonstrated that diosgenin induced apoptosis in colorectal cancer cell lines HCT-116 and HT-29. HT-29 cells have been reported to be one of the most resistant colorectal cancer cell lines to TRAIL-induced apoptosis. In this study, we investigated the effect of diosgenin on TRAIL-induced apoptosis in HT-29 cells. We showed that diosgenin sensitizes HT-29 cells to TRAIL-induced apoptosis. Mechanisms underlying this sensitization mainly involved diosgenin-induced p38 MAPK pathway activation and subsequent DR5 overexpression. Furthermore, we showed that diosgenin alone, TRAIL alone or combination treatment increased COX-2 expression and that the use of a COX-2 inhibitor further increased apoptosis induction.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoptosis / drug effects*
-
Blotting, Western
-
Cyclooxygenase 2 / metabolism
-
Diosgenin / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Synergism
-
Enzyme Inhibitors / pharmacology
-
HT29 Cells
-
Humans
-
Imidazoles / pharmacology
-
MAP Kinase Signaling System / drug effects
-
Microscopy, Phase-Contrast
-
Pyridines / pharmacology
-
Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism*
-
TNF-Related Apoptosis-Inducing Ligand / pharmacology*
-
Up-Regulation / drug effects
-
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
-
p38 Mitogen-Activated Protein Kinases / metabolism*
Substances
-
Enzyme Inhibitors
-
Imidazoles
-
Pyridines
-
Receptors, TNF-Related Apoptosis-Inducing Ligand
-
TNF-Related Apoptosis-Inducing Ligand
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
p38 Mitogen-Activated Protein Kinases
-
Diosgenin
-
SB 203580